Tg Therapeutics, Inc. · NASDAQ:TGTX
Tg Therapeutics — Jefferies Global Healthcare Conference 2018
20 slides from Tg Therapeutics's conference presentation, Jun 7, 2018
Slide 1: TG Therapeutics - Jefferies Global Healthcare Conference
Q £ TG Therapeutics Jefferies Global Healthcare Conference June 2018 TarGeting B-Cell Diseases __ sss
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or nu, ” ” phrases such as “anticipates”, “expects”, “plans”, “believes”, “intends”, and similar
Slide 3: Our Goal
ur GO To develop the best possible treatment for B-cell diseases (Cancers: CLL, FL, MZL, DLBCL and Autoimmune: MS, RA, Lupus, etc.) Ideally, developing curative combination regimens (solutions development v. drug development) fe) TG Therapeutics 3
Slide 4: PI3K delta
CK: PI3K(delta Pee sc
Slide 5: Umbralisib (TGR-1202) and Ublituximab (TG-1101)
Umbralisib (TGR-1202) Ublituximab (TG-1101) Next Generation PI3K delta Next Generation anti-CD20 inhibitor monoclonal antibody Overcomes 1%t generation | Glycoengineered for enhanced Toxicity potency over 1$t generation Activity in Rituxan refractory Activity across NHL and CLL : patients Shorter in
Slide 6: UNITY-CLL trial
* There are ~115,000 Americans living with CLL and ~20,000 newly diagnosed each year ¢ UNITY-CLL trial conducted under CLL UNITY-CLL Enrollment Complete 7 Randomize 7 Gazyva + CHL Special Protocol Assessment (SPA) Total Enrollment ° Le] expected to be the only novel doublet approved for BOTH newly-
Slide 7: UNITY-CLL: ORR Endpoint
UNITY.CLL: ORR endoont Targeting ~15% improvement in ORR (minimum detectable difference of ~13%) Gazyvat : Comps ca. Population U2 Comps CLL-11: Treatment ae carve ct | 75-78% | aig | 88-92% | resonate 218 ORR 82% HELIOS: Relapsed/ U/U2 ORR: 80- 8% Benda Ritx: | ie) . 0, creme | 92-60% | Refractory
Slide 8: UNITY-CLL: PFS Endpoint
UNITY-CLL: PFS Endpoint Integrated Analysis: Helios: Benda + Umbralisib + CLL-11: Umbralisib & U2 Rituxan Gazyva + CHL Gazvya + CHL (n=27) (n=183) (n=15) (n=289) Front Line 24+ months* |13.3 months |~36+months** |26.7months * Median PFS for Umbralisib Monotherapy: 24 Months; Median PFS not reached f
Slide 9: GENUINE Phase 3 Ublituximab + Ibrutinib
GENUINE Phase 3 iclel . GEN a | NE Ublituximab + Ibrutinib TG THERAPEUTICS GLYCOENGINEERED UBLITUXIMAB + IBRUTINIB Wu N = fe) Qa =z < ao Ibrutinib PHASE 3 TRIAL IN HIGH-RISK CLL Status: = Phase 3 Trial in Relapsed/Refractory High Risk CLL = Positive ORR Data Presented at ASCO 2017 = Potential Accele
Slide 10: Umbralisib and U2 in Previously Treated NHL
Umbralisib and U2 in ater NHL TG THERAPEUTICS GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA UMBRALISIB (TGR-1202) PREVIOUSLY TREATED NHL PATIENTS Includes three cohorts: FL, MZL and DLBCL brs Therapeutics 10
Slide 11: Follicular Lymphoma
Follicular Lymphoma rey ¢ Approximately 15,000 new cases per year with ~7,500 relapsed patients needing treatment per year * 53% ORR for umbralisib single agent at higher doses in r/r FL in UNITY-NHL Trial FL Cohort Currently Enrolling Umbralisib (TGR-1202) Monotherapy Phase 1 at higher doses (Publi
Slide 12: Marginal Zone Lymphoma (MZL)
Marginal Lymphoma (MZL) UNITY-NHL Trial Approximately 7,500 new cases MZL Cohort per year, with ~3,000 relapsed Currently Enrolling patients needing treatment each 7 Umbralisib year (TGR-1202) Monotherapy Ibrutinib recently approved with 46% ORR Target Enrollment ~60 Defined path for accelerated Tar
Slide 13: Diffuse Large B-cell Lymphoma (DLBCL)
¢ US annual incidence of ~20,000 new cases per year of which ~50- 60% cured with front-line treatment ¢ For those not cured, ~20% will be Diffuse Large B- cell Lymphoma (DLBCL) | UNITY-NHL Trial | DLBCL Cohort Currently Enrolling Ublituximab + Umbralisib + Benda eligible for, and obtain a cure from,
Slide 14: Umbralisib and U2 in B-cell Cancers: U.S. Market Opportunity
Umbralisib and U2 in B-cell Cancers U.S. Market Opportunity Company Estimates, Patients Current . Regimen Needing Treatment/Year | U2 CLL ~20,000 | Umbra FL ~7,500 | Umbra MZL ~3,000 U2 + Benda DLBCL ~6,000 CLL & NHL represents a multi-billion dollar opportunity for Umbralisib and U2 &£ TG Therapeut
Slide 15: Newly In-licensed TG-1701 and triple therapy data
ewly In- = TG-1701: orally available, covalently-bound BTK inhibitor » Phase 1 currently enrolling in China » TG sponsored Phase 1/2 trial to open 3Q18 Ublituximab + Umbralisib + Ibrutinib Best Percent Change from Baseline in Disease Burden . _ DUBCL fL meu Response Rate Observed with Triple Therapy
Slide 16: Ublituximab in Multiple Sclerosis
ituxime Anew study by the Nat'l MS ULTIMATE | & Il Society estimates that ~1,000,000 Phase 3 Clinical Americans are living with MS Trials Recently approved anti-CD20 sine oan (ocrelizumab) with first year sales approaching $1 B Ublituximab Placebo + Infusion + Placebo Teriflunomide ==, Will compete
Slide 17: Clinical Phase 2 Endpoints at Week 24
Clinical ml Enapene at Week 24 Ublituximab | Ocrelizumab Phase 2 Phase 2 (N=48) (N=55) Opera I&ll Endpoint (24 Weeks) |(24Weeks) (96 Weeks) Annualized Relapse Rate % Relapse Free Inglese et al., Presented at AAN Annual Meeting April 2018 Kappos L et al. Lancet. 2011; 378:1779-1787 Hauser SL. et al.
Slide 18: Inglese M et al., Presented at AAN Annual Meeting
Inglese M et al., Presented at AAN Annual Meeting, April 2018
Slide 19: Key Financial Statistics
Key Financial Statistics TGTX (NASDAQ) $14.55 (close on June 6, 2018) ~78M (fully-diluted) ~$123.3M (pro forma as of 3/31/18) Through mid-2019 ce) TG Therapeutics 19
Slide 20: TG Therapeutics
, § TG Therapeutics NASDAQ: TGTX
TG Therapeutics — Jefferies Global Healthcare Conference 2018 on 6ix